1. Germany Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
CytoTools AG

CytoTools AG

T5O.DE
CytoTools AGDE flagDeutsche Börse
0.32
EUR
- -
- -
164,400.00Market Cap
CytoTools AG
T5O.DE
(Deutsche Börse)

Recent

price

0.32

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
FRC
- -
0.32
0.26
0.26
0.24
1.4
- -
- -
0.37
- -
0.09
0.08
0.1
0.02
0.03
Revenue per Share
- -
-4.22
-4.19
-3.36
-5.36
-4.83
-5.79
-4.32
-4.43
-4.67
-3.07
-4.03
-8.89
-1.44
-36.28
Basic EPS, GAAP
- -
-9
-3.71
-3.62
-4.22
-4.33
-6.66
-4.51
-4.79
-4.18
-2.23
-3.64
-3.73
-1.58
-1.26
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-28.87
-27.35
-27.04
-32.52
-30.27
-35.73
-39.33
-41.03
-35.2
-31.11
-27.45
-36.34
-28.25
-64.53
Book Value per Share
- -
15.35
30.24
31.1
37.62
39.2
47.8
43.73
43.52
44.12
42.61
47.91
39.14
37.09
0.81
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-959.55
-1,277.82
-1,678.11
-1,383.61
-2,317.91
-346.06
- -
- -
-1,132.43
-120,972.71
-3,246.05
-5,105.99
-3,426.19
-6,727.68
-4,861.98
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
3
- -
20
Depreciation Expense
-1
-1
-1
-1
-1
-1
-1
-1
-1
-1
-1
-2
-4
-1
-21
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-1,355.81
-1,325.26
-1,645.02
-1,310.82
-2,270.18
-344.48
- -
- -
-1,185.93
-140,612.11
-3,523.77
-5,108.88
-9,095.43
-6,783.6
-120,369.08
Profit Margin (%)
1
2
3
1
2
1
3
1
2
- -
2
2
- -
2
1
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
4
2
6
6
8
9
11
10
11
14
18
22
18
21
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.68%
-8.3%
-97.81%
Free Cash Flow
4.49%
-2.33%
-20.09%
Net Income, GAAP
253.41%
499.91%
2,424.49%
Sales/Revenue/Turnover
- -
694.38%
42.27%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
-8.89
2022
- -
- -
- -
- -
-1.44
2023
- -
- -
- -
- -
-36.28

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
XOMA Corporation (XOMAO)
NLS Pharmaceutics AG (NLSPW)
Annexon, Inc. (ANNX)
Revolution Medicines, Inc. (RVMD)
Targovax ASA (TRVX.OL)
Altimmune, Inc. (ALT)
Business
bioXXmed AG (formerly CytoTools AG), a Germany-based holding company listed on the Basic Board of the Frankfurt Stock Exchange, invests equity in innovative biotechnology and medical technology companies focused on biomedicine, particularly dermatology and wound care; it provides financing through equity contributions, either alone or in consortium, while managing holdings as non-consolidated financial investments without conducting its own research and development. Founded in 2000 and headquartered in Darmstadt, Germany, the company holds a 68% stake in DermaTools Biotech GmbH, which develops products such as DermaPro, a dichloric acid-based solution for treating chronic wounds including diabetic foot ulcers and venous leg ulcers, and is the largest shareholder in CytoPharma GmbH, which advances therapies for cardiovascular diseases, cancer, urinary tract infections via Utisept bladder flushing device, and other indications encompassing small molecules and biologics targeting cell growth and programmed cell death mechanisms; geographic operations span Europe with regulatory pursuits in the European Union and United States, alongside prior licensing in India through partners like Centaur Pharmaceuticals. In September 2022, the company rebranded from CytoTools AG to bioXXmed AG to reflect its investment-holding focus; it acquired assets and contracts from the bankrupt DermaTools Biotech to sustain projects, notably advancing DermaPro toward medical device approval in Europe and the US; recent financials for the half-year ended June 30, 2025, report minimal sales of EUR 0.017 million and a net loss of EUR 0.256 million, amid intentions to raise capital for portfolio expansion in dermatology and wound care innovations.